Showing 1 - 5 results of 5 for search 'Kantarjian, H', query time: 0.03s
Refine Results
-
1
AML-348 A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies by Lachowiez, C, Borthakur, G, Loghavi, S, Zeng, Z, Kadia, T, Masarova, L, Takahashi, K, Tippett, G, Garcia, J, Bose, P, Jabbour, E, Ravandi, F, Daver, N, Manero, GG, Vyas, P, Kantarjian, H, Konopleva, M, DiNardo, C
Published 2022Conference item -
2
Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML) by DiNardo, C, Stein, A, Stein, E, Fathi, A, Frankfurt, O, Schuh, A, Doehner, H, Martinelli, G, Patel, P, Raffoux, E, Tan, P, Zeidan, A, De Botton, S, Kantarjian, H, Stone, R, Lam, D, Wang, X, Gong, J, Kapsalis, S, Hickman, D, Zhang, V, Winkler, T, Wu, B, Vyas, P
Published 2019Conference item -
3
A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies by Lachowiez, CA, Loghavi, S, Zeng, Z, Tanaka, T, Kim, YJ, Uryu, H, Turkalj, S, Jakobsen, NA, Luskin, MR, Duose, DY, Tidwell, RSS, Short, NJ, Borthakur, G, Kadia, TM, Masarova, L, Tippett, GD, Bose, P, Jabbour, EJ, Ravandi, F, Daver, NG, Garcia-Manero, G, Kantarjian, H, Garcia, JS, Vyas, P, Takahashi, K, Konopleva, M, DiNardo, CD
Published 2023Journal article -
4
MLL-rearranged acute lymphoblastic leukemias activate BCL-2 through H3K79 methylation and are sensitive to the BCL-2-specific antagonist ABT-199 by Benito, J, Godfrey, L, Kojima, K, Hogdal, L, Wunderlich, M, Geng, H, Marzo, I, Harutyunyan, K, Golfman, L, North, P, Kerry, J, Ballabio, E, Chonghaile, T, Gonzalo, O, Qiu, Y, Jeremias, I, Debose, L, O'Brien, E, Ma, H, Zhou, P, Jacamo, R, Park, E, Coombes, K, Zhang, N, Thomas, D, O'Brien, S, Kantarjian, H, Leverson, J, Kornblau, S, Andreeff, M, Müschen, M, Zweidler-McKay, P, Mulloy, J, Letai, A, Milne, T, Konopleva, M
Published 2015Journal article -
5
AML-262 Pivekimab Sunirine (PVEK, IMGN632) triplet with azacitidine and venetoclax shows broad activity in adverse genetic subsets of relapsed/refractory acute myeloid leukemia and... by Daver, N, Montesinos, P, Aribi, A, Martinelli, G, Altman, JK, Wang, ES, Roboz, GJ, Burke, PW, Gaidano, G, Walter, RB, Thomas, X, Jeyakumar, D, DeAngelo, DJ, Erba, HP, Todisco, E, Begna, K, Advani, A, Gastaud, L, de la Fuente, A, Curti, A, Mendez, LM, Vyas, P, Boissel, N, Vey, N, Recher, C, Longval, T, Platzbecker, U, Kapp-Schwörer, S, Schliemann, C, Konopleva, M, Torres, L, Sallman, DA, Marcucci, G, Marconi, G, Kantarjian, H, Sloss, CM, Malcolm, KE, Zweidler-McKay, PA, Sweet, K
Published 2022Journal article